convalescent plasma treatment - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.99 [0.93, 1.05]< 10%24 studies (24/-)63.9 %some concerncritical moderatecrucial-
deaths 0.98 [0.92, 1.04]< 10%37 studies (37/-)77.4 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.99 [0.79, 1.24]< 10%7 studies (7/-)54.7 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.87 [0.71, 1.06]< 19%5 studies (5/-)91.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.09 [0.87, 1.38]> 139%8 studies (8/-)77.9 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.27 [0.90, 5.72]> 10%1 study (1/-)95.9 %NAnot evaluable important-
clinical improvement (28-day) 1.33 [0.83, 2.14]> 153%5 studies (5/-)88.1 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.98 [0.27, 3.58]> 10%1 study (1/-)48.8 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.08 [0.90, 1.29]> 10%5 studies (5/-)80.5 %lownot evaluable highimportant-
death or ventilation 0.98 [0.94, 1.03]< 10%5 studies (5/-)79.2 %some concernnot evaluable moderateimportant-
hospital discharge 1.00 [0.94, 1.07]> 10%3 studies (3/-)52.3 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.83 [0.64, 1.08]< 124%7 studies (7/-)91.7 %some concernnot evaluable moderateimportant1
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
viral clearance 1.10 [0.19, 6.30]> 10%2 studies (2/-)54.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.96 [0.77, 1.20]> 10%2 studies (2/-)35.7 %some concernnot evaluable moderateimportant-
viral clearance by day 7 0.87 [0.65, 1.16]> 10%2 studies (2/-)17.4 %some concernnot evaluable moderateimportant-
ICU admission 0.67 [0.32, 1.41]< 11%2 studies (2/-)85.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.19 [0.94, 1.50]< 145%6 studies (6/-)7.8 %some concernnot evaluable moderateimportant-
adverse events 1.08 [0.86, 1.37]< 10%2 studies (2/-)24.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.